Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.

CONCLUSIONS: In this report of intermediate- and high-risk prostate cancer, continuously greater rates of decline PSA for duration 1, 2 and 3 year following SBRT boost after WPRT resulted in lower PSA nadir. Also, SBRT boost after WBPT leads to favorable BCF-free survival. PMID: 26969216 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26969216?dopt=Abstract

Source: Clinical Prostate Cancer - March 10, 2016 Category: Cancer & Oncology Authors: Kim HJ, Phak JH, Kim WC Tags: Asia Pac J Clin Oncol Source Type: research

More News: Cancer | Cancer & Oncology | Prostate Cancer | Study